Novartis highlights pipeline progress, shares trade steadily on NYSE

Novartis underlines progress in rare disease and radioligand therapies while recruitment for late-stage trials continues, keeping the pharma group in focus for NYSE investors.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-24, 08:29.

Novartis (CH0012005267) is drawing investor attention on the NYSE with progress in both rare muscle disease and radioligand therapies. The Swiss pharma group is advancing multiple late-stage programs after reporting promising trial data earlier in June, according to recent analyst and media coverage.Yahoo Finance summary of Novartis trial updates

Rare muscle disease candidate shows promise

On June 11, Novartis highlighted early to mid-stage trial results for an experimental treatment targeting facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disease that affects an estimated 87,000 people across the United States and Europe.Detailed report on the FSHD data The therapy, sourced via Novartis's roughly 12 billion dollar acquisition of Avidity Biosciences, reduced two blood biomarkers linked to muscle damage in trial participants.

Novartis has suggested that this candidate could become the first treatment to modify the progression of FSHD, moving beyond symptomatic care. Safety findings in the early trial phase were described as consistent with previous data, and the company is currently recruiting patients for a late-stage study in the same indication.FSHD late-stage recruitment commentary

Radioligand oncology program advances

Novartis is also progressing with a radiopharmaceutical drug based on the isotope actinium for advanced prostate cancer, adding another asset to its radioligand therapy franchise alongside Pluvicto. Initial study data showed prostate-specific antigen reductions in 101 patients, with over 85 percent of previously untreated individuals responding and 52.5 percent of patients who had already received Pluvicto also showing a response.Summary of actinium-based radiopharmaceutical results

Chief Medical Officer Shreeram Aradhye has emphasized the need for larger trials to evaluate potential side effects and durability of response. Analysts at TD Cowen have flagged dry mouth and severe anemia as notable risks while pointing out that Novartis is running two late-stage studies and is actively expanding its isotope supply arrangements to support potential commercial deployment.Analyst perspective from TD Cowen on safety and supply

The business behind the stock

Novartis generates most of its revenue from innovative prescription medicines, with key franchises in oncology, immunology and neuroscience. A prominent product in its portfolio is Kisqali, a CDK4/6 inhibitor used in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, which has become a core growth driver in recent years.Company information on Kisqali sales contribution

Where the Novartis shares trade today

Novartis shares (CH0012005267) last closed on the NYSE on 2026-06-23 at 153.37 US dollars, according to TradingKey data.TradingKey quote for NVS

Key data on the Novartis shares

• Company: Novartis AG
• ISIN: CH0012005267
• WKN: 904278
• Ticker: NVS
• Trading venue: NYSE
• Price (as of 2026-06-23, 16:00): 153.37 USD
• Market cap: 294.29 billion USD (as of 2026-06-23)
• Sector / industry: Pharmaceuticals
• Index membership: S&P 500 (via ADR representation)
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any transaction. All data are based on sources deemed reliable but cannot be guaranteed. Investors should conduct their own research or consult a licensed financial advisor before making investment decisions.